

METHOD

Pathway-based dissection of the genomic heterogeneity of cancer hallmarks with SLAPenrich

Francesco Iorio^{1,5†}, Luz Garcia-Alonso^{1,5}, Jonathan Brammell², Iñigo Martincorena², David R Wille^{3,5}, Ultan McDermott^{2,5} and Julio Saez-Rodriguez^{1,4,5*†}

Abstract

Extracting functional information from sequencing data is a main question of computational cancer genomics. We present a computational pipeline to characterize how cancers from different tissue types might have acquired canonical cancer hallmarks via preferential genomic alteration of different biological pathways. This is based on SLAPenrich, a statistical method implemented in an open source R package, to identify pathway-level enrichments of genetic alterations. We used SLAPenrich and a curated collection of 374 orthogonal pathway gene-sets encompassing 3,915 genes from public resources mapped to 10 canonical cancer hallmarks to characterise the landscape of pathway alterations contributing to the acquisition of different cancer hallmarks in 4,415 patients across 10 cancer types, from The Cancer Genome Atlas. We find that the heterogeneity of the significantly genomically altered pathways within certain hallmarks reflects their established predominance in determined cancer types and their clinical relevance.

In addition, although most of the pathway alteration enrichments and hallmark heterogeneities are guided by somatic mutations in established cancer driver genes, when excluding these variants from the analyses, the levels of predominance of the considered hallmarks are strikingly preserved across cancer types. Therefore we propose to use the obtained hallmark heterogeneity signatures as a ground truth to characterise long tails of infrequent genomic alterations across cancer types, and we highlight a number of potential novel cancer driver genes and networks.

Keywords: cancer-genomics; hallmark-analysis; pathways; populations; mutual-exclusivity; enrichment-analysis

Background

The swift progression of next-generation sequencing technologies is enabling a fast and affordable production of an extraordinary amount of genome sequences. Cancer research is particularly benefiting from these advances, and comprehensive catalogues of somatic mutations involved in carcinogenesis, tumour progression and response to therapy are becoming increasingly available and ready to be exploited for the identification of new diagnostic, prognostic and therapeutic markers [1, 2, 3, 4].

Exploration of the genomic makeup of multiple cancer types has highlighted that driver somatic muta-

tions typically involve few genes altered at high frequency and a long tail of more genes mutated at very low frequency [5, 6], with a tendency for both sets of genes to code for proteins involved into a limited number of biological processes [7]. As a consequence, a reasonable approach is to consider these alterations by grouping them based on prior knowledge of the cellular mechanisms and biological pathways where the products of the mutated genes operate [8]. This reduces the dimensionality of large genomic datasets involving thousands of altered genes into a sensibly smaller set of altered mechanisms that are more interpretable, and possibly actionable in a pharmacological or experimental way [9]. Additionally, thanks to the increased function interpretability, this grouping facilitates the identification of the possible alterations underpinning an evolutionary successful trait acquired by a normal cell as it transforms itself in a pretumoral

*Correspondence: iorio@ebi.ac.uk; saezrodriguez@gmail.com

¹European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, CB10 1SD Cambridge, UK
Full list of author information is available at the end of the article

† Co-corresponding author

one and ultimately into cancer. These traits have been summarised into a set of 11 principles, collectively referred as the *hallmarks of cancer* [10, 11].

Here we present a computational strategy, relying on the novel statistical tool SLAPEnrich, to characterise the set of genomically altered pathways contributing to the acquisition of the canonical cancer hallmarks and to quantify the predominance of each hallmark in each cancer type. We show results from applying this strategy to 10 different cancer types, via a systematic analysis of 4,415 publicly available cancer patients' genomes (from the Cancer Genome Atlas). After verifying that the majority of the cancer hallmark predominances are led by somatic mutations in established high-confidence cancer genes, we show that they are maintained when excluding these variants from the analysis. Thus we propose to use the obtained *heterogeneity signatures of cancer hallmarks* as the ground truth for functionally characterising long tails of infrequent genomic alterations, across cancer types. Finally we highlight a number of potential novel cancer driver genes and networks, identified with the proposed approach.

Results

Sample Level Analysis of Pathway Alterations Enrichments (SLAPEnrich)

In the first step of our implemented computational pipeline we make use of SLAPEnrich (Sample Level Analysis of Pathway alteration Enrichments): a computational method implemented into an R package to perform pathway analyses of genomic datasets at the sample-population level. We have designed this tool on purpose as a mean to characterize in an easily interpretable way sparse somatic mutations detected in heterogeneous cancer sample populations, which share traits of interest and are subjected to strong selective pressure, leading to combinatorial patterns.

Several computational methods have been designed to perform pathway analysis on genomic data, aiming at prioritizing sets of genomically altered genes whose products operate in the same cellular process or functional network. All the approaches proposed so far toward this aim can be classified into two main classes [8].


The first class of approaches aims at identifying pathways whose composing genes are significantly over-represented in the set of altered genes across all the samples of a dataset compared against the background set of all studied genes. Generally, a Fisher's

exact test is used to calculate the statistical significance of this over-representation. Many tools exist and are routinely used to perform this analysis [12, 13, 14], sometimes incorporating additional features, such as accounting for inter-gene dependencies and signal correlations [15].

To identify pathways, or any other gene sets, that are over-represented in a selected set of genes satisfying a certain property (for example, being differentially expressed), the likelihood of their recurrence in the gene set of interests is usually estimated. This is quantified through a p-value assignment computed through a hypergeometric (or Fisher exact) test, against the null hypothesis that there is no association between the pathway under consideration and the biological state yielding the selected set of genes. The test fail (producing a non significant p-value) when the overlap between the considered pathway and the set of genes of interests is close to that expected by random chance.

The problem we tackle with SLAPEnrich is rather different: we want to test the hypothesis that, in a given cohort of cancer patients, the number of samples harbouring a mutation in at least one gene belonging to a given pathway is significantly larger and divergent from its expectation, considering the size of the cohort, the background mutation rates of the individual samples and the (non-overlapping) total exonic block lengths of the genes. As a consequence, the first step is to model the probability of observing at least a mutation in a single gene belonging to the pathway under consideration across the individual samples. The second step is to aggregate these individual probabilities in a collective test against the null hypothesis that there is no association between the pathway under consideration and the genomic alterations observed in the analysed cohort. To our knowledge there are only two other publicly available tools to conduct this type of analyses: PathScan [16] and PathScore [17]. While they share commonalities with SLAPEnrich, several aspects make these two tools unsuitable for the analysis described in this manuscript (Supplementary Methods).

The second class of approaches aims at identifying novel pathways by mapping alteration patterns on large protein networks. The combinatorial properties occurring among the alterations are then analyzed and used to define cost functions, for example based on the tendency of a group of genes to be mutated in a mutual exclusive manner. On the basis of these cost functions, optimal sub-networks are identified and interpreted as novel cancer driver pathways [18, 19, 20].



However, at the moment there is no consensual way to rigorously define a mathematical metric for mutual exclusivity and compute its statistical significance, and a number of interpretations exist [18, 19, 21, 22, 23].

SLAPenrich does not require somatic mutations in a pathway to be statistically enriched among those detected in each sample nor the merged (or aggregated) set of mutations in the population. Relying on the mutual exclusivity principle [24], SLAPenrich assumes that a single mutation in a gene can be enough to deregulate the activity of the pathway, providing selective growth advantages. Hence, SLAPenrich belongs

roughly to the first category described above, although it shares the mutual exclusivity consideration with the methods in the second.

More precisely, after modeling the probability of a genomic alteration in at least one member of a given pathway across the individual samples, a collective statistical test is performed against the null hypothesis that the number of samples with at least one alteration in that pathway is close to that expected by random chance, therefore no association exists between the analyzed population and the pathway under consideration. An additional advantage of modeling prob-

abilities of at least an individual mutation in a given pathway (instead of, for example, the probability of the actual number of mutated genes) is that this prevent signal saturations due to hypermutated samples.

The input to SLAPenrich is a collection of samples accounting for the mutational status of a set of genes, such as a cohort of human cancer genomes. This is modeled as a dataset where each sample consists of a somatic mutation profile indicating the status (point-mutated or wild-type) of a list of genes (Figure 1A). For a given biological pathway P , each sample is considered as an individual Bernoulli trial that is successful when that sample harbors somatic mutations in at least one of the genes belonging to the pathway under consideration (Figure 1B).

The probability of success of each of these trials (i. e. observing a pathway with at least one mutation) is computed by either (i) a general hypergeometric model accounting for the mutation burden of the sample under consideration, the size of the gene background population and the number of genes in the pathway under consideration, or (ii) a more refined modeling of the likelihood of observing point mutations in a given pathway, accounting for the total exonic block lengths of the genes in that pathway (Figure 1AB) and the estimated (or actual) mutation rate of the sample under consideration [25]. In addition, more sophisticated methods, accounting for example for gene sequence compositions, trinucleotide rates, and other covariates (such as expression, chromatin state, etc) can be used through user-defined functions that can be easily integrated in SLAPenrich.

Once these probabilities have been computed, the expected number of samples in the population harboring at least one somatic mutation in P can be estimated, and its probability distribution modeled analytically. Based on this, a pathway alteration score can be computed observing the deviance of the number of samples harboring somatic mutations in P from its expectation, and its statistical significance quantified analytically (Figure 1C). Finally, the resulting statistically enriched pathways can be further filtered by looking at the tendency of their composing genes to be mutated in a mutually exclusive fashion across all the analyzed samples, as an additional evidence of positive selection [26, 18, 19].

SLAPenrich includes a visualization/report framework allowing an easy exploration of the outputted enriched pathways across the analyzed samples, in a way that highlights their mutual exclusivity mutation

trends, and a module for the identification of core-components genes, shared by related enriched pathways.

A formal description of the statistical framework underlying SLAPenrich is provided in the Methods; further details, results from a case study obtained applying SLAPenrich on a large lung adenocarcinoma genomic dataset, and a comparison with other similar tools are detailed in the Supplementary Methods, Supplementary Tables S1, S2, S3, S4 and S5, and Supplementary Figures S1, S2, and S3.


As detailed below, SLAPenrich can be used to systematically analyze large cohorts of cancer genomes providing a data-driven exploration of mutated pathways that can be easily compared across cancer types. Additionally, the format of the results allows a wide range of novel investigations at a high level of abstraction.

Mutational burdens at the pathway and gene level are not correlated

We performed SLAPenrich analyses of 10 different genomic datasets containing somatic point mutations, preprocessed as described in [27], from 4,415 patients across 10 different cancer types (results in Additional File 5). These dataset come from publicly available studies, in particular The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). These samples (see Methods) comprise breast invasive carcinoma (BRCA, 1,132 samples), colon and rectum adenocarcinoma (COREAD, 489), glioblastoma multiforme (GBM, 365), head and neck squamous cell carcinoma (HNSC, 375), kidney renal clear cell carcinoma (KIRC, 417), lung adenocarcinoma (LUAD, 388), ovarian serous cystadenocarcinoma (OV, 316), prostate adenocarcinoma (PRAD, 242), skin cutaneous melanoma (SKCM, 369), and thyroid carcinoma (THCA, 322).

We observed a weak correlation ($R = 0.53$, $p = 0.11$) between the number of enriched pathways across the different analyses and the number of available samples in the analysed dataset (Supplementary Figure S4A), but a down-sampled analysis showed that our results are not broadly confounded by the sample sizes (see Methods and Supplementary Figure S4B).

We investigated how our pathway enrichments capture known tissue specific cancer driver genes. To this aim, we used a list of high-confidence and tissue-specific cancer driver genes [27, 28] (from now high-confidence Cancer Genes, HCGs, assembled as described in the




Methods). We observed that the majority of the HCGs was contained in at least one SLAPenriched pathway, across the 10 different tissues analyses (median percentage = 63.5, range = 88.5%, for BRCA, to 28.7% for SKCM) (Supplementary Figure S4C).

Interestingly, we found that the number of SLAPenriched pathways per cancer type (median = 130, range = 55 for PRAD, to 200 for BRCA and COREAD) was independent from the average number of mutated genes per sample across cancer types (median = 46, range from 15 for THCA to 388 for SKCM) with a Pearson correlation $R = 0.16$ ($p = 0.65$), Figure 2A, as well as from the number of high confidence cancer driver genes (as predicted in [28], median = 100, range from 33 for THCA to 251 for SKCM, Figure 2B). Particularly, THCA has the lowest average number of mutations per sample (15.03), but there are 4 tissues with a lower number of pathways mutated. In contrast, SKCM has the highest average number of point mutations per sample (387.63), but the number of affected pathways is less than half of those of BRCA and GBM (82 enrichments against an average of 191), which have on average less than 100 mutations per sample (Figure 2). GBM, OV, KIRC, PRAD and BRCA are relatively homogeneous with respect to the average number of somatic mutations per sample (mean = 41.03, from 34.76 for KIRC to 45.95 for PRAD) but when looking at the number of enriched pathways for this set of cancer types we can clearly distinguish two separate groups (Figure 2). The first group includes BRCA and GBM that seem to have a more heterogeneous sets

of processes impacted by somatic mutations (average number of SLAPenriched pathways = 191) with respect to the second group (63 SLAPenriched pathways on average). These results suggest that there is a large heterogeneity in the number of processes deregulated in different cancer types that is independent of the mutational burden. This might be also indicative of different subtypes with dependencies on different pathways (and at least for BRCA this is expected) but could be also biased by the composition of the analysed cohorts being representative of a selected subtypes only.

SLAPenrich analyses across different cancer types highlights the heterogeneity of cancer hallmark acquisition

Subsequently, we reasoned that since the main role of cancer driver alterations is to enable cells to achieve a series of phenotypic traits called the ‘cancer hallmarks’ [10, 11], that can be linked to gene mutations [29], it would be informative to group the pathways according to the hallmark they are associated with. Towards this end, through a computer aided manual curation (see Methods and Supplementary Table S6) we were able to map 374 pathways to 10 cancer hallmarks [10, 11] (Figure 3AB), for a total number of 3,915 genes (included in at least one gene set associated to at least one hallmark; Supplementary Table 7). The vast majority (99%, 369 sets) of the considered pathway gene-sets were mapped on two hallmarks at most, and 298 of them (80%) was mapped onto one single hallmark



(Figure 3C). Regarding the individual genes contained in at least one pathway gene-set, about half (49%) were associated with a single hallmark, 22% with two, 12% with three, and 7% with four (Figure 3D). Finally, as shown in Figure 3E, the overlaps between the considered pathway gene-sets was minimal (74% of all the possible pair-wise Jaccard indexes was equal to 0 and 99% < 0.2). In summary, our manual curation produced a non-redundant matching in terms of both pathways- and genes-hallmarks associations.

Mapping pathway enrichments into canonical cancer hallmarks through this curation allowed us to explore how different cancer types might acquire the same hallmark by selectively altering different pathways (Figure 4, and Supplementary Figure S5). Heatmaps in these figures (one per each hallmark) show different level of enrichments of pathways associated to the same hallmark across different tissues.

We investigated at what extent the identified hallmark-associated enriched pathways were dominated by somatic mutations in the high-confidence cancer genes

(HCGs) [28], across cancer types. This analysis also highlights the ratio of these pathways with variant enrichments in potentially novel cancer driver genes and networks. To this aim, for each pathway P enriched in a given cancer type T , we computed an HCG-dominance score as the ratio between the number of T samples with mutations in HCGs belonging to P and the total number of T samples with mutations in any of the gene belonging to P . Results of this analysis are shown in Supplementary Figures S6 and S7. We observed a median of 15% of pathway enrichments, across hallmarks, with an HCG-dominance score $< 50\%$, thus potentially not led by somatic mutations in HCGs (range from 9% for *Deregulating Cellular Energetics* to 21% for *Genome Instability and Mutation*). Additionally, a median of 3% of pathway enrichments had a null HCG-dominance, thus not involved somatic mutations in HCGs (range from 0.25% for *Evading Growth Suppression* to 15% for *Avoiding Immune Destruction*). Across all the hallmarks, the cancer type with the lowest median HCG-dominance was KIRC (33%), whereas that with the highest was




Figure 4 Heterogeneity of hallmark acquisition across cancer types: Heatmaps showing pathway enrichments at the population level across cancer types for individual hallmarks (representative cases). Color intensities correspond to the enrichment significance. Cancer types and pathways are clustered using a correlation metric. See also additional figure 4.

THCA (91%).

Patterns and well defined clusters can be clearly distinguished in the heatmaps of Figure 4. As an example, the heatmap related to the *Genome Instability and mutation* hallmark shows that BRCA, OV, GBM, LUAD and HNSC might achieve this hallmark by selectively altering a group of pathways related to homologous recombination deficiency, whose prevalence in BRCA and OV is established [30]. This deficiency has been therapeutically exploited recently and translated into a clinical success thanks to the introduction of PARP inhibition as a very selective therapeutic option for these two cancer types [31].

Pathways preferentially altered in BRCA, OV, GBM, LUAD and HNSC include *G2/M DNA Damage Checkpoint // Processing Of DNA Double Strand Break Ends*, *TP53 Regulates Transcription Of DNA Repair Genes*, and other signaling networks related to BRCA1/2 and its associated RING Domain 1 (BARD1). Conversely, the *Androgen receptor* pathway, known to regulate the growth of glioblastoma multiforme (GBM) in men [32] is also exclusively and preferentially altered in this cancer type.

The acquisition of the *Genome Instability and mutation* hallmark seems to be dominated in COREAD by alterations in the *HDR Through Single Strand Annealing (SSA)*, *Resolution Of D Loop Structures Through Synthesis Dependent Strand Annealing (SDSA)*, *Homologous DNA Pairing And Strand Exchange* and other pathways more specifically linked to a microsatellite instability led hypermutator phenotype, known to be prevalent in this cancer type [33].

Finally, the heatmap for *Genome Instability and Mutation* shows nearly no enriched pathways for SKCM. This is consistent with the high burden of mutations observed in melanoma originating from cell extrinsic processes such as UV light exposure [34]. The maintenance of genomic integrity is guarded by a network of damage sensors, signal transducers, and mediators, and it is regulated through changes in gene expression. Recent studies show that miRNAs play a crucial role in the response to UV radiation in skin cells [35]. Our analysis strikingly detects *MiRNAs Involved In DNA Damage Response* as the unique pathway associated to *Genome instability and mutation* enriched in SKCM. This suggests that mutations in this pathway, involving ATM (as top frequently mutated gene, and known to induce miRNA biogenesis following DNA damage [36]), impair the ability of melanocytes to properly


respond to insult from UV light and may have a significant role in the tumorigenesis of melanoma.

The *Avoiding Immune destruction* heatmap (Figure 4) highlights a large number of pathways selectively enriched in COREAD, whereas very few pathways associated to this hallmark are enriched in the other analysed cancer types. This could explain why immunotherapies, such as PD-1 inhibition, have a relatively low response rate in COREAD when compared to, for example, non-small cell lung cancer [37], melanoma [38] or renal-cell carcinoma [39]. In fact, response to PD-1 inhibition in COREAD is limited to tumours with mismatch-repair deficiency, perhaps due to their high rate of neoantigen creation [40].

In the context of COREAD, the *Tumor-promoting inflammation* heatmap (Figure 4) also highlights several pathways predominantly and very specifically altered in this cancer type. Chronic inflammation is a proven risk factor for COREAD and studies in animal models have shown a dependency between inflammation, tumor progression and chemotherapy resistance [41]. Indeed, a number of clinical trials evaluating the utility of inflammatory and cytokine-modulatory therapies are currently underway in colorectal cancer [42, 43]. Interestingly, according to our analysis this hallmark is acquired by SKCM by exclusively preferentially altering IRF3 related pathways.

Several other examples would be worthy of mention. For example, the detection of the *Warburg effect* pathway contributing to the acquisition of the *Deregulating cellular energetics* hallmark in GBM only (Figure 4). The Warburg effect is a unique bioenergetic state of aerobic glycolysis, whose reversion has been recently proposed as an effective way to decrease GBM cell proliferation [44]. Additionally, the pathway *Formation of senescence associated heterochromatin*, associated to the *Enabling replicative immortality* hallmark is enriched in multiple cancer types. Genomic alterations in this pathway have not been linked to cancer so far. More interestingly the enrichment of this pathway, across cancer types, is not driven by any established cancer gene.

Finally, we quantified the diversity of pathways used to achieve each hallmark in a given cancer type, via a cumulative heterogeneity score (CHS) computed as the proportion of the pathways associated to that hallmark that are enriched. The larger this score the larger the number of different pathways a given cancer type alters in order to achieve the considered hallmark. A larger heterogeneity of pathways, in turn, could point



to the exploitation of more evolutionary trajectories (reflected by selecting genomic alterations in a larger number of associated pathways). If this holds true, the larger this score the more the evolutionary fitness of a cancer type may depend on acquiring the hallmark under consideration.

Joining the CHSs of all the hallmarks resulting from the analysis of a given cancer type, gives its *hallmark heterogeneity signature* (Figure 5). Results show consistency with the established predominance of certain hallmarks in determined cancer types, such as for example a high CHS for *Genome instability and mutation* in BRCA and OV [45], for *Tumour-promoting inflammation* and *Avoiding immune-destruction* in

COREAD [46]. Lastly, and as expected for *Sustaining proliferative-signaling* and *Enabling replicative immortality*, the key hallmarks in cancer initiation [10], high CHSs are observed across the majority of the analysed cancer types.

Taken together, these results show the potential of SLAPenrich to perform systematic landscape analyses of large cohorts of cancer genomes. In this case it allowed us to highlight commonalities and differences in the acquisition of the cancer hallmarks across tissue types, confirming several known relations between cancer types, and pinpointing preferentially altered pathways and hallmark acquisitions.

Hallmark heterogeneity analysis points at potential novel cancer driver genes and networks

To investigate the potential of SLAPenrich in identifying novel cancer driver genes and networks we performed a final analysis (from now the *filtered analysis*) after removing all the variants involving, for each considered cancer type, the corresponding High Confidence Genes (HCGs). Results of this exercise (Figure 6 and Supplementary Figure 8), showed that the majority of the enrichments identified in the original analyses (on the unfiltered genomic datasets) were actually led by alterations in the HCGs (consistent with their condition of high reliable cancer genes). The average ratio of retained enrichments in the filtered analyses across cancer types (maintained enrichments (MA) in Figure 6 and Supplementary Figure 8) was 21% (range from 2.1% for GBM to 56.2% for COREAD). However, several pathway enrichments (some of which did not include any HCGs) were still detected in the filtered analysis and, most importantly, the corresponding hallmark heterogeneity signatures were largely conserved between the filtered and unfiltered analyses for most of the cancer types, with coincident top fitting hallmarks and significantly high over-all correlations (Figure 6, Supplementary Figure 8). We assume that the hallmark signatures from the original unfiltered analyses provide a faithful representations of the mutational landscape of the analysed cancer types and their hallmark predominancies. Detecting the same hallmark predominancies, despite the removal of variants in HCGs (which are highly frequently mutated), indicates that the enrichment of hallmark-associated pathway in the filtered analysis is collectively led by mutations in novel and lowly frequently mutated cancer driver genes that are functionally interconnected (whole bulk of results in Additional File 7 and examples in Figure 7).

An example is represented by the pathway *Activation Of Matrix Metalloproteinases* associated with the *Invasion and metastasis* hallmark and highly enriched in the filtered analyses of COREAD (FDR = 0.002%), SKCM (0.09%) (Figure 7A), LUAD (0.93%), and HNSC (3.1%). The activation of the matrix metalloproteases is an essential event to enable the migration of malignant cells and metastasis in solid tumors [47]. Although this is a hallmark acquired late in the evolution of cancer, according to our analysis this pathway is still detectable as significantly enriched. As a consequence, looking at the somatic mutations of its composing genes (of which only Matrix Metalloproteinase 2 - MMP2 - has been reported as harboring cancer driving alterations in LUAD [28]) might reveal novel key components of this pathway leading to

metastatic transitions. Interestingly, among these, one of the top frequently mutated genes (across all the 4 mentioned cancer types) is Plasminogen (PLG), whose role in the evolution of migratory and invasive cell phenotype is established [48]. Furthermore, blockade of PLG with monoclonal antibodies, DNA-based vaccination or silencing through small interfering RNAs has been recently proposed to counteract cancer invasion and metastasis [49]. The remaining altered component of this pathway is mostly made of a network of very lowly frequently mutated (and in a high mutual exclusive manner) other metalloproteinases.

Another similar example is given by the *IL 6 Type Cytokine Receptor Ligand Interactions* pathway significantly enriched in the filtered analysis of SKCM (FDR = 4.6%) and associated with the *Tumour-promoting inflammation hallmark* (Figure 7B). IL-6-type cytokines have been observed to modulate cell growth of several cell types, including melanoma [50]. Increased IL-6 blood levels in melanoma patients correlate with disease progression and lower response to chemotherapy [51]. Importantly, studies proposed OSMR, a IL-6-type of cytokine receptor, to play a role in the prevention of melanoma progression [52], and as a novel potential target in other cancer types [53]. Consistently with these findings, OSMR is the member of this pathway with the largest number of mutations in the SKCM cohort (Figure 7B), complemented by a large number of other lowly frequently mutated genes (most of which are interleukins).

In the context of melanoma, we observed other two pathways highly enriched in the filtered analysis: *PDGF receptor signaling network* (FDR = 2.7%) (Figure 7C) and *Neurophilin Interactions with VEGF And VEGFR* (0.21%)(Figure 7D), both associated with the *Inducing angiogenesis* hallmark. Mutations in all the components of these two pathways are not common in SKCM and have not been highlighted in any genomic study so far. The first of these two pathway enrichments is characterised by patterns of highly mutually exclusive somatic mutations in Platelet-derived growth factor (PDGF) genes, and corresponding receptors: a network that has been recently proposed as an autocrine endogenous mechanism involved in melanoma proliferation control [54].

A final example is given by the enriched pathway *Regulating the activity of RAC1* (associated with the *Activating Invasion and Metastasis* hallmark) in COREAD (Figure 7E). The Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1) gene is a member of the Rho family of GTPases, whose activity is key for




Figure 6 Hallmark heterogeneity signature analysis with and without known drivers: In each row, the first circle plot show pathway enrichments at the population level when considering all the somatic variants (bars on the external circle) and when considering only variants not involving known high-confidence cancer driver genes (internal circle); the second circle plot compares the hallmark signatures resulting from SLAPenrich analysis including (bars on the external circle) or excluding (bars on the internal circle) the variants involving known high-confidence cancer genes. The bar plot shows a comparison, in terms of true-positive-rate (TPR) and positive-predicted-value (PPV), of the SLAPenriched pathways recovered in the filtered analysis vs. the complete analysis. The scatter plots on the right show a comparison between the resulting hallmark signatures.

cell motility [55]. Previous *in vitro* and *in vivo* studies in prostate cancer demonstrated a marked increase in RAC1 activity in cell migration and invasion, and that RAC1 inhibition immediately stopped these processes [56, 57]. However, although the role of RAC1 in enabling metastasis has already been suggested, the mechanisms underlying such aberrant behaviour are poorly understood, and our findings could be used as a starting point for further investigations [58].

Another interesting case is the high level of mutual exclusivity observed in the mutation patterns involving members of the *TP53 network*, highly enriched in the filtered analysis of SKCM, encompassing TP63, TP73, TNSF10, MYC and SUMD1 (Figure 7F). Whereas alterations in some nodes of this network are known to be an alternative to p53 repression, conferring chemoresistance and poor prognosis [59], dissecting the functional relations between them is still widely considered a formidable challenge [60]. Our results point out alternative players worthy to be looked at in this network (particularly, among the top frequently altered, TNSF10).

Taken together, these results suggest that our computational strategy, supported by SLAPenrich, can help to identify potential novel cancer driver genes and cancer driver networks composed by lowly frequently mutated genes.

Discussion

In this paper we presented a computational pipeline, with a paired statistical framework implemented in an open source R package (SLAPenrich), to identify genomic alterations in biological pathways contributing in the acquisition of the canonical cancer hallmarks. Our statistical framework does not seek for pathways whose alterations are enriched at the individual sample level nor at the global level, i.e. considering the union of all the genes altered in at least one sample. Instead, SLAPenrich searches for pathway alterations representative of the population, considering the individual contribution of each member. It assumes that an individual mutation involving a given pathway in a given sample might be sufficient to deregulate the activity of that pathway in that sample and it allows enriched pathways to be mutated in a mutual exclusive manner across samples.

The SLAPenrich package includes (i) fully tunable functions where statistical significance criteria and alternative models, can be defined by the user; (ii) a visualization and reporting framework, and (iii) accessory functions for data management and gene identifier curation and cross-matching. Worthy of note is


that many different tools provide the possibility of visualizing a mutual-exclusivity sorted sets of somatic mutations and other genomic alterations from publicly available or user defined datasets via a browser accessible software suite (e.g. GiTools [61] and cBioPortal [62]) or as a result of combinatorial pattern analysis (such as MEMo [63] and Dendrix [19]). However, none of these tools offer this feature as a mean to visualise an arbitrarily defined data matrix and, to our knowledge, there is no publicly available R implementation for this.

Beyond extraction of pathway enrichments, as illustrated with our case study on a lung cancer data set, we used SLAPenrich to perform large-scale comparative analysis of cancer mutational landscapes. In this way we have characterised the functional mutational landscape of cancer hallmarks across different cancer types. The obtained results provide a first data-driven landmark exploration of hallmark acquisitions through the preferential alteration of heterogenous sets of pathways across cancer types. The ratio of pathways mutated per hallmark seems to reflect established hallmark predominancies, and highlights peculiar patterns of altered pathways for certain cancer types. Finally, by using the identified hallmark signatures as the gold-standard signal, we re-performed SLAPenrich analyses after the removal of variants in established cancer genes and highlighted genes that contributed to those hallmarks as potential novel cancer driver genes and networks.

A number of possible limitations could hamper deriving definitive conclusions from this paper, such as the use of only mutations, the possibility that some of the analysed cohorts of patients are representative only of well-defined disease subtypes, or the limitation of our knowledge of pathways.

Nevertheless, we provide the community with a useful tool for the analysis of large genomic datasets, whose produced results (as in our hallmark analysis presented here) could open a wide range of novel *in-silico* investigations.

Additionally, the computational tool supporting our strategy (SLAPenrich), could be of wide usability for the functional characterization of sparse genomic data from heterogeneous populations sharing common traits and subjected to strong selective pressure. For example, SLAPenrich could be of great utility in other scenarios such as the characterization of genomic data generated upon chemical mutagenesis to identify somatic mutations involved in acquired drug resistance



[Brammell et al, under revision <http://dx.doi.org/10.1101/066555>]. More generally, SLAPenrich can be used to characterize at the pathway level any type of biological dataset that can be modeled as a presence/absence matrix, where genes are on the rows and samples are on the columns.

Methods

Formal description of the SLAPenrich statistical framework

Let us consider the list of all the genes $G = \{g_1, g_2, \dots, g_n\}$, whose somatic mutational status has been determined across a population of samples $S = \{s_1, s_2, \dots, s_m\}$, and a function $f : G \times S \rightarrow \{0, 1\}$ defined as

$$f(g, s) = \begin{cases} 1 & \text{if } g \text{ harbours a somatic mutation in } s \\ 0 & \text{otherwise} \end{cases} \quad (1)$$

Given the set of all the genes whose products belong to the same pathway P , we aim at assessing if there is a statistically significant tendency for the samples in S to carry mutations in P . Importantly, we do not require the genes in P to be significantly enriched in those that are altered in any individual sample nor in the sub-set of G composed by all the genes harbouring at least one somatic mutation in at least one sample. In what follows P will be used to indicate the pathway under consideration as well as the corresponding set of genes, interchangeably. We assume that P is altered in sample s_i if $\exists g \in G$ such that $g \in P$ and $f(g, s_i) = 1$, i.e. at least one gene in the pathway P is altered in the i -th sample (Figure 1B). To quantify how likely it is to observe at least one gene belonging to P altered in sample s_i , we introduce the variable $X_i = |\{g \in G : g \in P \text{ and } f(g, s_i) = 1\}|$, accounting for the number of genes in P altered in sample s_i . Under the assumption of both a gene-wise and sample-wise statistical independence, the probability of X_i assuming a value greater or equal than 1 is given by:

$$p_i = \Pr(X_i \geq 1) = \sum_{x=1}^k H(x, N, k, n_i), \quad (2)$$

where N is the size of the gene background-population, k is the number of genes in P , n_i is the total number of genes g such that $f(g, s_i) = 1$, i.e. the total number of genes harbouring an alteration in sample s_i , and H is the probability mass function of a hypergeometric distribution:

$$H(x, N, k, n_i) = \frac{\binom{k}{x} \binom{N-k}{n_i-x}}{\binom{N}{n_i}}. \quad (3)$$

To take into account the impact of the exonic lengths $\lambda(g)$ of the genes (g) on the estimation of the alteration probability of the pathway they are part of P , it is possible to redefine the p_i probabilities (of observing at least one genes in the pathway P altered in sample s_i) as follows:

$$p_i = \Pr(X_i \geq 1) = \sum_{x=1}^k H(x, N', k', n'_i), \quad (4)$$

where $N' = \sum_{g \in G} \lambda(g)$, with G the gene background-population, i.e. the sum of all the exonic content block lengths of all the genes; $k' = \sum_{g \in P} \lambda(g)$ is the sum of the exonic block length of all the genes in the pathway P ; n'_i is the total number of individual point mutations involving genes belonging to P in sample s_i , and H is defined as in equation 3, but with parameters x, N', k' , and n'_i . Similarly, the p_i probabilities can be modeled accounting for the total exonic block lengths of all the genes belonging to P and the expected/observed background mutation rate [25], as follows:

$$p_i = \Pr(X_i \geq 1) = 1 - \exp(-\rho k'), \quad (5)$$

where k' is defined as for equation 4 and ρ is the background mutation rate, which can be estimated from the input dataset directly or set to established estimated values (such as 10^{-6} /nucleotide)[25]. If considering the event “the pathway P is altered in sample s_i ” as the outcome of a single test in a set of Bernoulli trials $\{i\}$ (with $i = 1, \dots, M$) (one for each sample in S), then each p_i can be interpreted as the success probability of the i -th trial. By definition, summing these probabilities across all the elements of S (all the trials) gives the expected number of successes $E(P)$, i.e. the expected number of samples harbouring a mutation in at least one gene belonging to P :

$$E(P) = \sum_{i=1}^M p_i. \quad (6)$$

On the other hand, if we consider a function ϕ on the domain of the X variables, defined as $\phi(X) = 1 - \delta(X)$, where $\delta(X)$ is the Dirac delta function (assuming null value for every $X \neq 0$), i.e. $\phi(X) = \{1 \text{ if } X > 0, \text{ and } 0 \text{ otherwise}\}$, then summing the $\phi(X_i)$ across all the samples in S , gives the observed number of

samples harbouring a mutation in at least one gene belonging to P :

$$O(P) = \sum_{i=1}^M \phi(X_i). \quad (7)$$

A pathway alteration index, quantifying the deviance of $O(P)$ from its expectation, and thus how surprising is to find so many samples with alterations in the pathway P , can be then quantified as:

$$\Delta(P) = \log_{10} \frac{O(P)}{E(P)}. \quad (8)$$

To assess the significance of such deviance, let us note that the probability of the event $O(P) = y$, with $y \leq M$, i.e. the probability of observing exactly y samples harbouring alterations in the pathway P , distributes as a Poisson binomial B (a discrete probability distribution modeling the sum of a set of $\{i\}$ independent Bernoulli trials where the success probabilities p_i are not identical (with $i = 1, \dots, M$). In our case, the i -th Bernoulli trial accounts for the event “the pathway P is altered in the sample s_i ” and its success probability of success is given by the $\{p_i\}$ introduced above (and computed with one amongst 2, 4, or 5). The parameters of such B distribution are then the probabilities $\pi = \{p_i\}$, and its mean is given by Equation 6. The probability of the event $O(P) = y$ can be then written as

$$\Pr(O(P) = y) = B(\pi, y) = \sum_{A \in F_y} \prod_{i \in A} p_i \prod_{j \in A^c} (1 - p_j), \quad (9)$$

where F_y is the set of all the possible subsets of y elements that can be selected from the trial $1, 2, \dots, M$ (for example, if $M = 3$, then $F_2 = \{\{1, 2\}, \{1, 3\}, \{2, 3\}\}$, and A^c is the complement of A , i.e. $\{1, 2, \dots, M\} \setminus A$). Therefore a p-value can be computed against the null hypothesis that $O(P)$ is drawn from a Poisson binomial distribution parametrised through the vector of probabilities π . Such p-value can be derived for an observation $O(P) = z$, with $z \leq M$, as (Figure 1C):

$$\Pr(O(P) \geq z) = \sum_{i=z}^M \Pr(O(P) = i) = \sum_{i=z}^M B(\pi, i) \quad (10)$$

Finally, p-values resulting from testing all the pathways in the considered collection are corrected for multiple hypothesis testing with a user-selected method among (in decreasing order of stringency) Bonferroni, Benjamini-Hochberg, and Storey-Tibshirani [64].

Pathway gene sets collection and pre-processing

To highlight the versatility of SLAPenrich and guarantee results’ comparability with respect to previously published studies, we have conducted the analyses described in the Results section using different collections of pathway gene sets, all included (as R objects) in our software package.

For the case study analysis on the LUAD dataset we downloaded the whole collection of KEGG [65] pathway gene sets from MsigDB [66], encompassing 189 gene sets for a total number of 5,224 genes included in at least one set.

The following differential enrichment analyses and the hallmark signature analyses were performed on a larger collection of pathway gene sets from the Pathway Commons data portal (v8, 2016/04) [67] (www.pathwaycommons.org). This contained an initial catalogue of 2,794 gene sets (one for each pathway) that were assembled from multiple public available resources, such as Reactome [68], Panther [69], HumanCyc [70], pid [71], smpdb [72], KEGG [65], ctd [73], inoh [74], wikipathways [75], netpath [76], and mirtarbase [77], and covering 15,281 unique genes.

From this pathway collection, those gene sets containing less than 4 or more than 1,000 genes, were discarded. Additionally, in order to remove redundancies, those gene sets (*i*) corresponding to the same pathway across different resources or (*ii*) with a large overlap (Jaccard index (J) > 0.8 , as detailed below) were merged together by intersecting them. The gene sets resulting from this compression were then added to the collection (with a joint pathway label) and those participating in at least one of these merging were discarded. Finally, gene names were updated to their most recent HGNC [78] approved symbols (this updating procedure is also executed by a dedicate function in of the SLAPenrich package, by default on each genomic datasets prior the analysis). The whole process yielded a final collection of 1,911 pathway gene sets, for a total number of 1,138 genes assigned to at least one gene set.

Given two gene sets P_1 and P_2 the corresponding $J(P_1, P_2)$ is defined as:

$$J(P_1, P_2) = \frac{|P_1 \cap P_2|}{|P_1 \cup P_2|}. \quad (11)$$

Curation of a pathway/hallmark map

We implemented a simple routine (included in the SLAPenrich R package) that assigns to each of the 10 canonical cancer hallmarks a subset of the pathways in a given collection. To this aim this routine searches for determined keywords (typically processes or cellular components) known to be associated to each hallmark in the name of the pathway (such as for example: 'DNA repair' or 'DNA damage' for the *Genome instability and mutations* hallmark) or for key nodes in the set of included genes or key word in their name prefix (such as for example 'TGF', 'SMAD', and 'IFN' for *Tumour-promoting inflammation*). The full list of keywords used in this analysis are reported in the additional file 5. Results of this data curation are reported in the additional file 6.

Mutual exclusivity filter

After correcting the p-values yielded by testing all the pathways in a given collection, the enriched pathways can be additionally filtered based on a mutual exclusivity criterion, as a further evidence of positive selection. To this aim, for a given enriched pathway P , an exclusive coverage score $C(P)$ is computed as

$$C(P) = 100 \frac{O'(P)}{O(P)} \quad (12)$$

where $O(P)$ is the number of samples in which at least one gene belonging to the pathway P is mutated, and $O'(P)$ is the number of samples in which exactly one gene belonging to the pathway gene-set P is mutated. All the pathways P such that $C(P)$ is at least equal to a chosen value pass this final filter.

Hallmark heterogeneity signature analysis: genomic datasets and high-confidence cancer genes

Tissue specific catalogues of genomic variants for 10 different cancer types (breast invasive carcinoma, colon and rectum adenocarcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, prostate adenocarcinoma, skin cutaneous melanoma, and thyroid carcinoma) were downloaded from the GDSC1000 data portal described in [27] (www.cancerrxgene.org/gdsc1000/). This resource (available at www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources/Data/suppData/Tables2B.xlsx) encompasses variants from sequencing of 6,815 tumor normal sample pairs derived from 48 different sequencing studies [28] and reannotated using a pipeline consistent with the COSMIC database [79] (Vagrant: <https://zenodo.org/record/16732#.VbeVY2RViko>). Lists of tissue specific high-confidence cancer genes [28] were downloaded from the same data portal (http://www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources/Data/suppData/Tables2A.xlsx). These were identified by combining complementary signals of positive selection detected through different state of the art methods [80, 81] and further filtered as described in [27] (<http://www.cell.com/cms/attachment/2062367827/2064170160/mmc1.pdf>).

www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources/Data/suppData/Tables2B.xlsx) encompasses variants from sequencing of 6,815 tumor normal sample pairs derived from 48 different sequencing studies [28] and reannotated using a pipeline consistent with the COSMIC database [79] (Vagrant: <https://zenodo.org/record/16732#.VbeVY2RViko>). Lists of tissue specific high-confidence cancer genes [28] were downloaded from the same data portal (http://www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources/Data/suppData/Tables2A.xlsx). These were identified by combining complementary signals of positive selection detected through different state of the art methods [80, 81] and further filtered as described in [27] (<http://www.cell.com/cms/attachment/2062367827/2064170160/mmc1.pdf>).

Hallmark heterogeneity signature analysis: Individual SLAPenrich analysis parameters

All the individual SLAPenrich analyses were performed using the SLAPE.analyse function of the SLAPenrich R package (<https://github.com/francescojm/SLAPenrich>) using a Bernoulli model for the individual pathway alteration probabilities across all the samples, the set of all the genes in the dataset under consideration as background population, selecting pathways with at least one gene point mutated in at least 5% of the samples and at least 2 different genes with at least one point mutation across the whole dataset, and a pathway gene sets collection downloaded from pathway commons[67], post-processed for redundancy reduction as explained in the previous sections, and embedded in the SLAPE package as R data object:

```
PATHCOM_HUMAN_nonredundant_intersection_hugoUpdated.RData).
```

A pathway in this collection was considered significantly enriched, and used in the follow-up computation of the hallmark cumulative heterogeneity score, if the SLAPenrichment false discovery rate (FDR) was less than 5% and its mutual exclusive coverage (EC) was greater than 50%.

Down-sampling analyses

To investigate how differences in sample size might bias the SLAPenrichment results due to a potential tendency for larger datasets to produce larger number of SLAPenriched pathways, down-sampled SLAPenrich analyses were conducted for the 5 datasets with more than 350 samples (for BRCA, COREAD, GBM, HNSC, LUAD). Particularly, for $n \in \{800, 400, 250\}$ for BRCA and $n = 250$ for the other cancer types, 50 different SLAPenrich analyses were performed on n samples randomly selected from the genomic dataset

of the cancer type under consideration, with the parameter specifications described in the previous section. The average number of enriched pathways (FDR < 5% and EC > 50%) across the 50 analysis was observed.

Hallmark signature analysis: signature quantification

For a given cancer type C and a given hallmark H a cumulative heterogeneity score (CHS) was quantified as the ratio of the pathways associated to H in the SLAPenrich analysis of the C variants.

The CDS scores for all the 10 hallmark composed the hallmark signature of C .

Additional Files

- Additional file 1 — Supplementary Methods
- Additional file 2 — Legends of Supplementary Figures and Tables
- Additional file 3 — Supplementary Figures S1 to S8
- Additional file 4 — Supplementary Tables S1 to S7
- Additional file 5 — SLAPenrich results across 10 cancer types
- Additional file 6 — Exposed functions of SLAPenrich R-package
- Additional file 7 — Novel cancer driver networks

Availability of data and material

R code and data-objects are available at:

<https://github.com/francescojm/SLAPenrich>.

Pre-processed data sources are specified in the Methods.

Funding

OpenTargets funds JSR (Projects OpenTargets15 and OpenTargets16).

Competing interests

FI is an associated editor for a Biomed Central Journal. All the other authors declare that they have no competing interests.

Author's contributions

FI designed the statistical framework underlying SLAPenrich, conceived the hallmark heterogeneity analysis, and designed the other heuristic algorithms, conceived the visualization framework, implemented the R package, and wrote the manuscript; LGA contributed to the implementation of the visualization functions, tested and contributed to implementing the R package, curated data, and contributed to manuscript writing and revising; JB contributed to testing the R package, interpreted results and findings, contributed to manuscript writing and revising; IM contributed to the design of the validation analyses, read and edited the manuscript; DRW contributed to the design of the statistical framework and supervised its mathematical formalization; UM contributed to the interpretation of results; JSR supervised the study and contributed to the manuscript writing and revising.

Acknowledgements

We would like to thank Jorge Buendía, Mathew Garnett, and Annalisa "Lilla" Mupo for a number of insightful discussions, David Tamborero and Nuria Lopez-Bigas for critical feedback on the manuscript.

Author details

¹European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, CB10 1SD Cambridge, UK.

²Wellcome Trust Sanger Institute, Wellcome Genome Campus, CB10 1SD Cambridge, UK. ³GlaxoSmithKline, Gunnels Wood Rd, SG1 2NY Stevenage Herts, UK. ⁴Joint Research Centre for Computational

Biomedicine (JRC-COMBINE), RWTH Aachen University, Faculty of Medicine, MT12 Wendlingweg 2, 52074 Aachen, Germany. ⁵OpenTargets, Wellcome Genome Campus, CB10 1SD Cambridge, UK.

References

1. Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M.: The Cancer Genome Atlas Pan-Cancer analysis project. *Nature genetics* **45**(10), 1113–1120 (2013)
2. Consortium, T.I.C.G., committee, E., committee, E., policy, group, T., clinical annotation working, group, T.w., group, B.a.w., group, D.c., management working, Data release, d.t., publications working group, centre, D.c., committee, I.d.a., Australia, C.g.p.P.c.d.a., ovarian cancer serous adenocarcinoma, Canada, P.c.d.a., China, G.c.i., diffuse-type, European Union/France, R.c.r.c.c.f.o.b.n.l.t.c.c.s., European Union/United Kingdom, B.c.s.d.b.a.a.o.E.H.d.-t., France, B.c.s.d.b.a.a.o.t.H.g., France, L.c.h.c.s.t.a., adiposity, Paediatric brain tumours medulloblastoma, p.p.a.G., India, O.c.g., pancreatic tumours enteropancreatic endocrine tumours, R., rare pancreatic exocrine tumours; intraductal papillary mucinous neoplasms, s.p.t.m.c.n., other rarer tumours Italy, Japan, L.c.h.c.v.a., Spain, C.I.I.w.m., unmutated IgVH, United Kingdom, B.c.t.n., United States, T.C.G.A., committee, I.s.p.: PERSPECTIVES. *Nature* **464**(7291), 993–998 (2010)
3. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R.J., Bignell, G.R., Tam, A.T., Davies, H., Stevenson, J.A., Barthorpe, S., Lutz, S.R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J.L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H.G., Chang, J.W., Baselga, J., Stamenkovic, I., Engelman, J.A., Sharma, S.V., Delattre, O., Saez-Rodriguez, J., Gray, N.S., Suttleman, J., Futreal, P.A., Haber, D.A., Stratton, M.R., Ramaswamy, S., McDermott, U., Benes, C.H.: Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature* **483**(7391), 570–575 (2012)
4. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M.F., Monahan, J.E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F.A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I.H., Cheng, J., Yu, G.K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M.D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R.C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J.P., Gabriel, S.B., Getz, G., Ardlie, K., Chan, V., Myer, V.E., Weber, B.L., Porter, J., Warmuth, M., Finan, P., Harris, J.L., Meyerson, M., Golub, T.R., Morrissey, M.P., Sellers, W.R., Schlegel, R., Garraway, L.A.: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**(7391), 603–607 (2012)
5. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G.: Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature* **505**(7484), 495–501 (2014)
6. Garraway, L.A., Lander, E.S.: Lessons from the Cancer Genome. *Cell* **153**(1), 17–37 (2013)
7. Stratton, M.R., Campbell, P.J., Futreal, P.A.: The cancer genome. *Nature* **458**(7239), 719–724 (2009)
8. Creixell, P., Reimand, J., Haider, S., Wu, G., Shibata, T., Vazquez, M., Mustonen, V., Gonzalez-Perez, A., Pearson, J., Sander, C., Raphael, B.J., Marks, D.S., Ouellette, B.F.F., Valencia, A., Bader, G.D., Boutros, P.C., Stuart, J.M., Linding, R., Lopez-Bigas, N., Stein, L.D.: Pathway and network analysis of cancer genomes. *Nature Methods* **12**(7), 615–621 (2015)
9. Pe'er, D., Hacoen, N.: Principles and strategies for developing network models in cancer. *Cell* **144**(6), 864–873 (2011)
10. Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. *Cell* **144**(5), 646–674 (2011)
11. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Kinzler, K.W.: Cancer Genome Landscapes. *Science (New York, NY)* **339**(6127), 1546–1558 (2013)
12. Reimand, J., Arak, T., Vilo, J.: g:Profiler—a web server for functional interpretation of gene lists (2011 update). *Nucleic Acids Research* **39**(suppl), 307–315 (2011)

13. Eden, E., Navon, R., Steinfeld, I., Lipson, D., Yakhini, Z.: GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. *BMC bioinformatics* **10**(1), 48 (2009)
14. Huang, D.W., Sherman, B.T., Lempicki, R.A.: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols* **4**(1), 44–57 (2008)
15. Wu, D., Smyth, G.K.: Camera: a competitive gene set test accounting for inter-gene correlation. *Nucleic Acids Research* **40**(17), 133–133 (2012)
16. Wendl, M.C., Wallis, J.W., Lin, L., Kandath, C., Mardis, E.R., Wilson, R.K., Ding, L.: PathScan: a tool for discerning mutational significance in groups of putative cancer genes. *Bioinformatics* **27**(12), 1595–1602 (2011)
17. Gaffney, S.G., Townsend, J.P.: PathScore: a web tool for identifying altered pathways in cancer data. *Bioinformatics* (2016)
18. Ciriello, G., Cerami, E., Sander, C., Schultz, N.: Mutual exclusivity analysis identifies oncogenic network modules. *Genome Research* **22**(2), 398–406 (2012)
19. Vandin, F., Upfal, E., Raphael, B.J.: De novo discovery of mutated driver pathways in cancer. *Genome Research* **22**(2), 375–385 (2012)
20. Schubert, M., Iorio, F.: Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. *Pharmacogenomics* **15**(16), 1943–1946 (2014)
21. Li, H.T., Zhang, J., Xia, J., Zheng, C.H.: Identification of driver pathways in cancer based on combinatorial patterns of somatic gene mutations. *Neoplasia* **63**(1), 57–63 (2016)
22. Lu, S., Lu, K.N., Cheng, S.-Y., Hu, B., Ma, X., Nystrom, N., Lu, X.: Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. *PLoS computational biology* **11**(8), 1004257 (2015)
23. Constantinescu, S., Szczurek, E., Mohammadi, P., Rahnenführer, J., Beerwinkel, N.: TiMEx: a waiting time model for mutually exclusive cancer alterations. *Bioinformatics* (2015)
24. Yeang, C.H., McCormick, F., Levine, A.: Combinatorial patterns of somatic gene mutations in cancer. *The FASEB Journal* **22**(8), 2605–2622 (2008)
25. Youn, A., Simon, R.: Identifying cancer driver genes in tumor genome sequencing studies. *Bioinformatics* **27**(2), 175–181 (2011)
26. Thomas, R.K., Baker, A.C., DeBiasi, R.M., Winckler, W., LaFramboise, T., Lin, W.M., Wang, M., Feng, W., Zander, T., MacConaill, L.E., Lee, J.C., Nicoletti, R., Hatton, C., Goyette, M., Girard, L., Majumdar, K., Ziaugra, L., Wong, K.-K., Gabriel, S., Beroukhi, R., Peyton, M., Barretina, J., Dutt, A., Emery, C., Greulich, H., Shah, K., Sasaki, H., Gazdar, A., Minna, J., Armstrong, S.A., Mellinghoff, I.K., Hodi, F.S., Dranoff, G., Mischel, P.S., Cloughesy, T.F., Nelson, S.F., Liao, L.M., Mertz, K., Rubin, M.A., Moch, H., Loda, M., Catalona, W., Fletcher, J., Signoretti, S., Kaye, F., Anderson, K.C., Demetri, G.D., Dummer, R., Wagner, S., Herlyn, M., Sellers, W.R., Meyerson, M., Garraway, L.A.: High-throughput oncogene mutation profiling in human cancer. *Nature genetics* **39**(3), 347–351 (2007)
27. Iorio, F., Knijnenburg, T.A., Vis, D.J., Bignell, G.R., Menden, M.P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., Cokelaer, T., Greninger, P., van Dyk, E., Chang, H., de Silva, H., Heyn, H., Deng, X., Egan, R.K., Liu, Q., Mironenko, T., Mitropoulos, X., Richardson, L., Wang, J., Zhang, T., Moran, S., Sayols, S., Soleimani, M., Tamborero, D., Lopez-Bigas, N., Ross-Macdonald, P., Esteller, M., Gray, N.S., Haber, D.A., Stratton, M.R., Benes, C.H., Wessels, L.F.A., Saez-Rodriguez, J., McDermott, U., Garnett, M.J.: A Landscape of Pharmacogenomic Interactions in Cancer. *Cell* (2016)
28. Rubio-Perez, C., Tamborero, D., Schroeder, M.P., Antolin, A.A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., Lopez-Bigas, N.: In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. *Cancer Cell* **27**(3), 382–396 (2015)
29. Knijnenburg, T.A., Bismeyer, T., Wessels, L.F.A., Shmulevich, I.: A multilevel pan-cancer map links gene mutations to cancer hallmarks. *Chinese journal of cancer* **34**(10), 439–449 (2015)
30. Manié, E., Popova, T., Battistella, A., Tarabeux, J., Caux-Moncoutier, V., Golmard, L., Smith, N.K., Mueller, C.R., Mariani, O., Sigal-Zafrani, B., Dubois, T., Vincent-Salomon, A., Houdayer, C., Stoppa-Lyonnet, D., Stern, M.-H.: Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. *International Journal of Cancer* **138**(4), 891–900 (2016)
31. Walsh, C.S.: Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. *Gynecologic oncology* **137**(2), 343–350 (2015)
32. Yu, X., Jiang, Y., Wei, W., Cong, P., Ding, Y., Xiang, L., Wu, K.: Androgen receptor signaling regulates growth of glioblastoma multiforme in men. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine* **36**(2), 967–972 (2015)
33. Boland, C.R., Goel, A.: Microsatellite instability in colorectal cancer. (2010)
34. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-L., Boyault, S., Burkhardt, B., Butler, A.P., Caldas, C., Davies, H.R., Desmedt, C., Eils, R., Eyfjörð, J.E., Foekens, J.A., Greaves, M., Hosoda, F., Hutter, B., Illicic, T., Imbeaud, S., Imielinski, M., Imielinski, M., Jäger, N., Jones, D.T.W., Jones, D., Knappskog, S., Kool, M., Lakhani, S.R., López-Otín, C., Martin, S., Munshi, N.C., Nakamura, H., Northcott, P.A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J.V., Puente, X.S., Raine, K., Ramakrishna, M., Richardson, A.L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T.N., Span, P.N., Teague, J.W., Totoki, Y., Tutt, A.N.J., Valdés-Mas, R., van Buuren, M.M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L.R., Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMLL-Seq Consortium, ICGC PedBrain, Zucman-Rossi, J., Futreal, P.A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S.M., Siebert, R., Campo, E., Shibata, T., Pfister, S.M., Campbell, P.J., Stratton, M.R.: Signatures of mutational processes in human cancer. *Nature* **500**(7463), 415–421 (2013)
35. Syed, D.N., Khan, M.I., Shabbir, M., Mukhtar, H.: MicroRNAs in skin response to UV radiation. *Current drug targets* **14**(10), 1128–1134 (2013)
36. Zhang, X., Wan, G., Berger, F.G., He, X., Lu, X.: The ATM kinase induces microRNA biogenesis in the DNA damage response. *Molecular cell* **41**(4), 371–383 (2011)
37. Garon, E.B., Rizvi, N.A., Hui, R., Leigh, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.-J., Felip, E., Lee, J.-S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.-C., Dolled-Filhart, M., Rutledge, R.Z., Zhang, J., Luceford, J.K., Rangwala, R., Lubiniecki, G.M., Roach, C., Emancipator, K., Gandhi, L., KEYNOTE-001 Investigators: Pembrolizumab for the treatment of non-small-cell lung cancer. *The New England journal of medicine* **372**(21), 2018–2028 (2015)
38. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., Ribas, A., KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in Advanced Melanoma. *The New England journal of medicine* **372**(26), 2521–2532 (2015)
39. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tsykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., Castellano, D., Choueiri, T.K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauder, T.C., Ueda, T., Tomita, Y., Schutz, F.A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J.S., Xu, L.-A., Waxman, I.M., Sharma, P., CheckMate 025 Investigators: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *The New England journal of medicine* **373**(19), 1803–1813 (2015)
40. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Lubner, B.S., Azad, N.S., Laheru, D., Biedrzycki, B., Donehower, R.C., Zaheer, A., Fisher, G.A., Crocenzi, T.S., Lee, J.J., Duffy, S.M., Goldberg, R.M., de la Chapelle, A., Koshiji, M., Bhajee, F., Huebner, T., Hruban, R.H., Wood, L.D., Cuka, N., Pardoll, D.M., Papadopoulos, N., Kinzler, K.W., Zhou, S., Cornish, T.C., Taube, J.M., Anders, R.A., Eshleman, J.R., Vogelstein, B., Diaz, L.A.: PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *The New England journal of medicine* **372**(26), 2509–2520 (2015)

41. Jess, T., Rungoe, C., Peyrin-Biroulet, L.: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* **10**(6), 639–645 (2012)
42. West, N.R., McCuaig, S., Franchini, F., Powrie, F.: Emerging cytokine networks in colorectal cancer. *Nature reviews. Immunology* **15**(10), 615–629 (2015)
43. Lasry, A., Zinger, A., Ben-Neriah, Y.: Inflammatory networks underlying colorectal cancer. *Nature immunology* **17**(3), 230–240 (2016)
44. Poteet, E., Choudhury, G.R., Winters, A., Li, W., Ryou, M.-G., Liu, R., Tang, L., Ghorpade, A., Wen, Y., Yuan, F., Keir, S.T., Yan, H., Bigner, D.D., Simpkins, J.W., Yang, S.-H.: Reversing the Warburg effect as a treatment for glioblastoma. *Journal of Biological Chemistry* **288**(13), 9153–9164 (2013)
45. Pikor, L., Thu, K., Vucic, E., Lam, W.: The detection and implication of genome instability in cancer. *Cancer metastasis reviews* **32**(3-4), 341–352 (2013)
46. Grivennikov, S.I., Greten, F.R., Karin, M.: Immunity, inflammation, and cancer. *Cell* **140**(6), 883–899 (2010)
47. Deryugina, E.I., Quigley, J.P.: Matrix metalloproteinases and tumor metastasis. *Cancer metastasis reviews* **25**(1), 9–34 (2006)
48. Rabbani, S.A., Mazar, A.P.: The role of the plasminogen activation system in angiogenesis and metastasis. *Surgical oncology clinics of North America* **10**(2), 393–415 (2001)
49. Kumari, S., Malla, R.: New Insight on the Role of Plasminogen Receptor in Cancer Progression. *Cancer growth and metastasis* **8**, 35–42 (2015)
50. Zarling, J.M., Shoyab, M., Marquardt, H., Hanson, M.B., Liubin, M.N., Todaro, G.J.: Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. *Proceedings of the National Academy of Sciences of the United States of America* **83**(24), 9739–9743 (1986)
51. Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, I., Pouillart, P., Fridman, W.H.: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. *British journal of cancer* **69**(5), 911–913 (1994)
52. Lacreusette, A., Nguyen, J.-M., Pandolfino, M.-C., Khammari, A., Dreno, B., Jacques, Y., Godard, A., Blanchard, F.: Loss of oncostatin M receptor beta in metastatic melanoma cells. *Oncogene* **26**(6), 881–892 (2007)
53. Caffarel, M.M., Coleman, N.: Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. *The Journal of pathology* **232**(4), 386–390 (2014)
54. Faraone, D., Aguzzi, M.S., Toietta, G., Facchiano, A.M., Facchiano, F., Magenta, A., Martelli, F., Truffa, S., Cesareo, E., Ribatti, D., Capogrossi, M.C., Facchiano, A.: Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. *Neoplasia (New York, NY)* **11**(8), 732–742 (2009)
55. Yamazaki, D., Kurisu, S., Takenawa, T.: Regulation of cancer cell motility through actin reorganization. *Cancer science* **96**(7), 379–386 (2005)
56. Bid, H.K., Roberts, R.D., Manchanda, P.K., Houghton, P.J.: RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. *Molecular Cancer Therapeutics* **12**(10), 1925–1934 (2013)
57. Bailey, C.L., Kelly, P., Casey, P.J.: Activation of Rap1 promotes prostate cancer metastasis. *Cancer research* **69**(12), 4962–4968 (2009)
58. Lee, J.-W., Ryu, Y.-K., Ji, Y.-H., Kang, J.H., Moon, E.-Y.: Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4. *Oncotarget* **6**(12), 9820–9833 (2015)
59. Matin, R.N., Chikh, A., Chong, S.L.P., Mesher, D., Graf, M., Sanza, P., Senatore, V., Scatolini, M., Moretti, F., Leigh, I.M., Proby, C.M., Costanzo, A., Chiorino, G., Cerio, R., Harwood, C.A., Bergamaschi, D.: p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. *The Journal of experimental medicine* **210**(3), 581–603 (2013)
60. Costanzo, A., Pediconi, N., Narcisi, A., Guerrieri, F., Belloni, L., Fausti, F., Botti, E., Levrero, M.: TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. *FEBS letters* **588**(16), 2590–2599 (2014)
61. Perez-Llamas, C., Lopez-Bigas, N.: Gitoools: analysis and visualisation of genomic data using interactive heat-maps. *PLoS ONE* **6**(5), 19541 (2011)
62. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., Schultz, N.: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science signaling* **6**(269), 1 (2013)
63. Ciriello, G., Cerami, E., Aksoy, B.A., Sander, C., Schultz, N.: Using MEMo to discover mutual exclusivity modules in cancer. *Current protocols in bioinformatics / editorial board, Andreas D. Baxeavanis ... [et al.]* **Chapter 8**, 8–17 (2013)
64. Storey, J.D., Tibshirani, R.: Statistical significance for genomewide studies. *Proceedings of the National Academy of Sciences of the United States of America* **100**(16), 9440–9445 (2003)
65. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M.: KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Research* **44**(D1), 457–62 (2016)
66. Subramanian, A., Tamayo, P., Mootha, V., Mukherjee, S., Ebert, B., Gillette, M., Paulovich, A., Pomeroy, S., Golub, T., Lander, E.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America* **102**(43), 15545 (2005)
67. Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, Ö., Anwar, N., Schultz, N., Bader, G.D., Sander, C.: Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Research* **39**(Database issue), 685–90 (2011)
68. Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., Jassal, B., Jupe, S., Matthews, L., May, B., Palatnik, S., Rothfels, K., Shamovsky, V., Song, H., Williams, M., Birney, E., Hermjakob, H., Stein, L., D'Eustachio, P.: The Reactome pathway knowledgebase. *Nucleic Acids Research* **42**(Database issue), 472–7 (2014)
69. Mi, H., Lazareva-Ulitsky, B., Loo, R., Kejariwal, A., Vandergriff, J., Rabkin, S., Guo, N., Muruganujan, A., Doremiex, O., Campbell, M.J., Kitano, H., Thomas, P.D.: The PANTHER database of protein families, subfamilies, functions and pathways. *Nucleic Acids Research* **33**(Database issue), 284–8 (2005)
70. Caspi, R., Billington, R., Ferrer, L., Foerster, H., Fulcher, C.A., Keseler, I.M., Kothari, A., Krummenacker, M., Latendresse, M., Mueller, L.A., Ong, Q., Paley, S., Subhraveti, P., Weaver, D.S., Karp, P.D.: The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. *Nucleic Acids Research* **44**(D1), 471–80 (2016)
71. Schaefer, C.F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., Buetow, K.H.: PID: the Pathway Interaction Database. *Nucleic Acids Research* **37**(Database issue), 674–9 (2009)
72. Frolkis, A., Knox, C., Lim, E., Jewison, T., Law, V., Hau, D.D., Liu, P., Gautam, B., Ly, S., Guo, A.C., Xia, J., Liang, Y., Shrivastava, S., Wishart, D.S.: SMPDB: The Small Molecule Pathway Database. *Nucleic Acids Research* **38**(Database issue), 480–7 (2010)
73. Grondin, C.J., Davis, A.P., Wieggers, T.C., King, B.L., Wieggers, J.A., Reif, D.M., Hoppin, J.A., Mattingly, C.J.: Advancing Exposure Science through Chemical Data Curation and Integration in the Comparative Toxicogenomics Database. *Environmental health perspectives* (2016)
74. Yamamoto, S., Sakai, N., Nakamura, H., Fukagawa, H., Fukuda, K., Takagi, T.: INOH: ontology-based highly structured database of signal transduction pathways. *Database : the journal of biological databases and curation* **2011**, 052 (2011)
75. Kutmon, M., Riutta, A., Nunes, N., Hanspers, K., Willighagen, E.L., Bohler, A., Mélius, J., Waagmeester, A., Sinha, S.R., Miller, R., Coort, S.L., Cirillo, E., Smeets, B., Evelo, C.T., Pico, A.R.: WikiPathways: capturing the full diversity of pathway knowledge. *Nucleic Acids Research* **44**(D1), 488–94 (2016)
76. Kandasamy, K., Mohan, S., Raju, R., Keerthikumar, S., Kumar, G.S.S., Venugopal, A.K., Telikicherla, D., Navarro, D.J., Mathivanan, S., Pecquet, C., Gollapudi, S.K., Tattikota, S.G., Mohan, S., Padhukasahasram, H., Subbannaya, Y., Goel, R., Jacob, H.K.C., Zhong, J., Sekhar, R., Nanjappa, V., Balakrishnan, L., Subbiah, R.,

- Ramachandra, Y.I., Rahiman, A., Keshava Prasad, T.s., Lin, J.-X., Houtman, J.C.D., Desiderio, S., Renauld, J.-C., Constantinescu, S., Ohara, O., Hirano, T., Kubo, M., Singh, S., Khatri, P., Draghici, S., Bader, G.D., Sander, C., Leonard, W.J., Pandey, A.: NetPath: a public resource of curated signal transduction pathways. *Genome Biology* **11**(1), 3 (2010)
77. Chou, C.-H., Chang, N.-W., Shrestha, S., Hsu, S.-D., Lin, Y.-L., Lee, W.-H., Yang, C.-D., Hong, H.-C., Wei, T.-Y., Tu, S.-J., Tsai, T.-R., Ho, S.-Y., Jian, T.-Y., Wu, H.-Y., Chen, P.-R., Lin, N.-C., Huang, H.-T., Yang, T.-L., Pai, C.-Y., Tai, C.-S., Chen, W.-L., Huang, C.-Y., Liu, C.-C., Weng, S.-L., Liao, K.-W., Hsu, W.-L., Huang, H.-D.: miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. *Nucleic Acids Research* **44**(D1), 239–47 (2016)
78. Wain, H.M., Bruford, E.A., Lovering, R.C., Lush, M.J., Wright, M.W., Povey, S.: Guidelines for human gene nomenclature. *Genomics* **79**(4), 464–470 (2002)
79. Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., Kok, C.Y., Jia, M., De, T., Teague, J.W., Stratton, M.R., McDermott, U., Campbell, P.J.: COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Research* **43**(Database issue), 805–11 (2015)
80. Gonzalez-Perez, A., Lopez-Bigas, N.: Functional impact bias reveals cancer drivers. *Nucleic Acids Research* **40**(21), 169 (2012)
81. Tamborero, D., Gonzalez-Perez, A., Lopez-Bigas, N.: OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. *Bioinformatics* **29**(18), 2238–2244 (2013)